While these cohorts represent different glioma sub-entities with distinct molecular pathophysiology, the average survival times are vastly different, particularly between oligodendroglioma (IDH-mutant, 1p/19q co-deleted) and GBM (IDH-wildtype, 1p19q non-co-deleted), and thus divergent epitranscriptomic regulator expression patterns may relate to the very different biology of these distinct pathological entities [101]. This evidence concerns the gene IDH1 and glioma.